Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001086631 | SCV000645407 | likely benign | Dystonia 12 | 2024-01-21 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000538377 | SCV001143140 | likely benign | not provided | 2019-03-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000538377 | SCV001949765 | benign | not provided | 2019-02-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002260002 | SCV002539992 | benign | Alternating hemiplegia of childhood 2 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002260003 | SCV002539993 | benign | Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002260004 | SCV002539994 | benign | Developmental and epileptic encephalopathy 99 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001086631 | SCV002539996 | benign | Dystonia 12 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004553233 | SCV004104075 | uncertain significance | ATP1A3-related disorder | 2023-01-30 | criteria provided, single submitter | clinical testing | The ATP1A3 c.2692G>A variant is predicted to result in the amino acid substitution p.Val898Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.12% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-42473622-C-T), which may be too common to be causative of disease. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ce |
RCV000538377 | SCV004143848 | benign | not provided | 2022-08-01 | criteria provided, single submitter | clinical testing | ATP1A3: BS1, BS2 |